PTC
NBIX icon

Private Trust Company’s Neurocrine Biosciences NBIX Stock Holding History

Private Trust Company’s Portfolio NBIX Stock Details NBIX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		– Sell
-90
Closed -$11.3K – 2632
2025
Q2 		$11.3K Sell
90
-62
-41% -$7.11K ﹤0.01% 1773
2025
Q1 		$16.8K Buy
152
+17
+13% +$2.15K ﹤0.01% 1629
2024
Q4 		$18.4K Sell
135
-1
-0.7% -$124 ﹤0.01% 1513
2024
Q3 		$15.7K Buy
136
+91
+202% +$12.5K ﹤0.01% 1566
2024
Q2 		$6.2K Hold
45
– – ﹤0.01% 1851
2024
Q1 		$6.21K Sell
45
-5
-10% -$683 ﹤0.01% 1829
2023
Q4 		$6.59K Buy
+50
New +$5.75K ﹤0.01% 1815
2023
Q2 		– Sell
-70
Closed -$7.08K – 2349
2023
Q1 		$7.08K Sell
70
-2
-3% -$208 ﹤0.01% 1716
2022
Q4 		$9K Buy
72
+11
+18% +$1.29K ﹤0.01% 1595
2022
Q3 		$6K Buy
+61
New +$6.19K ﹤0.01% 1625
2014
Q4 		– Sell
-631
Closed -$10K – 861
2014
Q3 		$10K Hold
631
– – ﹤0.01% 1113
2014
Q2 		$9K Hold
631
– – ﹤0.01% 1129
2014
Q1 		$10K Buy
+631
New +$10.8K ﹤0.01% 979

Other funds holding NBIX

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dodge & Cox
Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $218B AUM 29.41% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

Private Trust Company's NBIX Position: Q3 2025 in Review

Private Trust Company sold out of Neurocrine Biosciences (NBIX) in Q3 2025, closing a stake of 90 shares — an estimated $11.3K sold.

Private Trust Company first reported a position in NBIX in Q1 2014 and held it in 13 quarters. The position peaked at $18.4K in Q4 2024. 649 funds tracked by Wall St. Rank hold NBIX as of Q3 2025.

  • Private Trust Company reported no remaining Neurocrine Biosciences position as of Q3 2025 after selling out during the quarter.
  • Private Trust Company sold 90 Neurocrine Biosciences shares in Q3 2025, an estimated $11.3K.
  • Private Trust Company first reported a position in Neurocrine Biosciences in Q1 2014 and held it in 13 quarters.
  • Private Trust Company's Neurocrine Biosciences position peaked at $18.4K in Q4 2024.
  • 649 funds tracked by Wall St. Rank held Neurocrine Biosciences as of Q3 2025.

Based on Private Trust Company's 13F filing for Q3 2025, filed 15 Oct 2025.